Developer docs
API playgroundTry for free, no card

Search company profiles

Wockhardt

Full company profile

uuid0002mcn

Namestring
Wockhardt
Legal namestring
Wockhardt Limited
Websiteurl
wockhardt.com
Company typeenum
Public
Founded yearint
1967
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersMumbai, India
HQ citystring
Mumbai
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
novel antibiotic development, pharmaceutical manufacturing, biosimilar insulin products, active pharmaceutical ingredients, branded generic medicines
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceuticals
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Branded Generics - India & Emerging Markets
TypeOne Time License
Description

Wockhardt generates significant revenue from its portfolio of branded generic pharmaceuticals sold across India and emerging markets. The company has a strong presence in anti-infectives, with established brands in the Indian pharmaceutical market. Revenue is generated through a network of distributors and field sales representatives targeting hospitals and retail pharmacies.

2Biosimilars
TypeOne Time License
Description

Wockhardt has developed and commercializes biosimilar products, including a recent launch of a biosimilar pegfilgrastim (Pegficel) in India. These biologic products provide an alternative to expensive originator biologics and generate revenue through hospital and retail pharmacy channels.

3Novel Antibiotics - Zaynich (US & Global Markets)
TypeOne Time License
Description

Following FDA approval, Wockhardt is commercializing Zaynich directly in the US market through its own sales force targeting hospital systems. This represents a shift from traditional generic pricing to branded pharmaceutical pricing with premium positioning justified by clinical differentiation and addressing unmet medical needs in antimicrobial resistance.

4Contract Manufacturing
TypeProfessional Services
Description

Wockhardt operates contract manufacturing services leveraging its USFDA and EMA-approved manufacturing facilities. The company manufactures active pharmaceutical ingredients (APIs) and finished dosage forms for global pharmaceutical companies, providing a steady revenue stream with typically lower margins than branded products.

Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure
Pricing details2 tiers
1Zaynich pricing in US market at premium positioning
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Zaynich is priced at $10,000-$12,000 per treatment course in the US market, reflecting premium pricing for novel antibiotics addressing drug-resistant infections. This pricing positions Zaynich competitively against other novel beta-lactam/beta-lactamase inhibitor combinations used in hospitals for serious gram-negative infections. The pricing is significantly lower than competitors for equivalent treatment courses while offering clinical advantages.

2Zaynich pricing in India at significantly reduced rates
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Zaynich pricing in India is positioned at 75-80% lower than US pricing, making it significantly more accessible for Indian patients. This differential pricing strategy reflects Wockhardt's commitment to ensuring access to novel antibiotics in developing markets while maintaining commercial viability through US market revenues.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 6 records shown
1ZAYNICH (Zidebactam/Cefepime)
Description

Novel antibiotic for complicated urinary tract infections, first NCE fully developed by an Indian pharma company to receive US FDA approval

wockhardt.com
+5 more records
Core offering1 text field

Wockhardt discovers, develops, manufactures, and commercializes pharmaceutical products with a primary focus on novel antibiotics targeting drug-resistant bacterial infections. Its commercial portfolio includes ZAYNICH, EMROK, EMROK O, and Miqnaf/Nafithromycin, alongside biosimilars (Glaritus, Wosulin, Wepox), active pharmaceutical ingredients (APIs), contract manufacturing services for global pharma companies, and a broad branded generics portfolio sold across India and emerging markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • First Indian company to receive FDA approval for a novel antibiotic addressing drug-resistant gram-negative infections
+2 more records
Product overview1 text field

Wockhardt is a research-based pharmaceutical company operating as an integrated enterprise with 'Concept to Commercialisation' capabilities. The company's product portfolio centers on novel antibiotic discovery, with key products including ZAYNICH (a novel IV antibiotic for resistant Gram-negative infections), EMROK/EMROK O (novel antibiotics for MRSA and Gram-positive infections), Nafithromycin/Miqnaf (respiratory antibiotics), and WCK 4282/WCK 6777 (pipeline antibiotics targeting multi-drug resistant pathogens). The biologics division offers insulin products including Glaritus (biosimilar insulin glargine), Wosulin (human insulin), and Wepox (erythropoietin). Additional business segments include Active Pharmaceutical Ingredients (one of the largest Dextromethorphan HBr manufacturers globally), contract manufacturing services across 15 facilities, and quality generic pharmaceuticals. The company holds 45 patents in biosimilar development and 16 patents for insulin pen technology.

Product and service12 records
1ZAYNICH (Zidebactam/Cefepime - WCK 5222)
CategoryNovel antibiotics - anti-infectives
Description

Novel intravenous antibiotic combining Zidebactam with Cefepime, targeting multi-drug resistant Gram-negative bacteria causing complicated urinary tract infections including pyelonephritis. Designed for hospitalized patients with carbapenem-resistant infections; offered to US hospitals at $10,000-$12,000 per treatment course and at 75-80% lower pricing in India.

2EMROK (Levonadifloxacin - WCK 771)
CategoryNovel antibiotics - anti-infectives
Description

First-in-class antibiotic derived from the benzoquinolizine structural sub-class, approved for acute bacterial skin and skin structure infections including diabetic-foot infections and concurrent bacteraemia caused by Gram-positive pathogens including MRSA. Designated QIDP by US FDA.

3EMROK O (Alalevonadifloxacin - WCK 2349)
CategoryNovel antibiotics - anti-infectives
Description

Oral antibiotic prodrug of levonadifloxacin with approximately 90% oral bioavailability, designed for MDR Gram-positive MRSA infections. No dose adjustments required for renal or hepatic impairment. Designated QIDP by US FDA.

4Miqnaf (Nafithromycin - WCK 4873)
CategoryNovel antibiotics - anti-infectives
Description

Novel oral respiratory antibiotic with an ultra-short-course dosing regimen (800mg once-daily for 3 days) for treatment of community-acquired bacterial pneumonia. Highly potent against respiratory pathogens regardless of azithromycin, penicillin, or quinolone resistance. Designated QIDP by US FDA.

5WCK 4282 (Cefepime/Tazobactam)
CategoryPipeline antibiotics - anti-infectives
Description

Globally patented, pharmacodynamically optimised high-dose combination of cefepime and tazobactam for ESBL-producing Gram-negative pathogens, designed as a superior replacement for piperacillin/tazobactam in Phase 3 development. Designated QIDP by US FDA.

6WCK 6777 (Ertapenem/Zidebactam)
CategoryPipeline antibiotics - anti-infectives
Description

Once-daily IV antibiotic combination designed as outpatient parenteral antimicrobial therapy (OPAT) for multi-drug resistant Gram-negative infections. Phase 1 trials completed in the US with NIAID/NIH; granted Fast Track designation and QIDP status by US FDA.

7Glaritus (Insulin Glargine)
CategoryBiosimilars - diabetes
Description

Long-acting biosimilar insulin glargine (100IU/ML) for diabetes treatment, available in vials and cartridges with an in-house developed insulin pen. Backed by 16 globally valid patents for the insulin pen valid until 2035.

8Wosulin (Recombinant Human Insulin)
CategoryBiosimilars - diabetes
Description

Recombinant human insulin (r-DNA origin) for diabetes management, sold primarily in India and emerging markets.

9Wepox (Recombinant Erythropoietin)
CategoryBiosimilars - anemia
Description

Recombinant human erythropoietin (r-DNA origin) available in 10 strengths for anemia treatment, marketed globally.

10Active Pharmaceutical Ingredients (APIs)
CategoryActive pharmaceutical ingredients
Description

Active pharmaceutical ingredients manufactured for global supply, including position as one of the largest manufacturers of Dextromethorphan HBr API globally. Over 140 ANDAs in the US and over 60 EU CTD format dossiers developed using complex technologies.

11Contract Manufacturing Services
CategoryContract manufacturing services
Description

Contract manufacturing of APIs and finished dosage forms for global pharmaceutical companies, leveraging 12-15 facilities approved by UK MHRA, ANVISA, Gulf GCC, WHO GMP, and US FDA. Full turnkey services from development to high-volume commercial manufacture, including sterile manufacturing capabilities (notably for vaccines and injectables).

12Quality Generics Portfolio
CategoryBranded and generic pharmaceuticals
Description

Extensive portfolio of generic pharmaceuticals spanning antibiotics, cardiac medications, analgesics, corticosteroids, proton pump inhibitors, and other therapeutic categories, marketed globally including India, UK, Ireland, Russia-CIS, and emerging markets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-15
Description

Strategic manufacturing partnership for vaccine production in the UK, leveraging Wockhardt's fill-finish capabilities and regulatory-approved manufacturing facilities. This partnership enabled rapid deployment of COVID-19 vaccines in the UK market during the pandemic, demonstrating Wockhardt's ability to serve as a trusted manufacturing partner for global health initiatives.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Wockhardt manufactured the Oxford-AstraZeneca COVID-19 vaccine (Covishield) for the Indian market, utilizing its fill-finish capabilities and regulatory infrastructure. This partnership involved technology transfer and manufacturing scale-up to produce hundreds of millions of vaccine doses.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partnership with BIRAC (Biotechnology Industry Research Assistance Council) for development of novel antibiotics addressing antimicrobial resistance. BIRAC has supported Wockhardt's R&D programs through funding and regulatory facilitation, reflecting the government's commitment to building indigenous pharmaceutical innovation capabilities.

Strategic tierMinorTypeOthers
Description

Intellectual property settlement and licensing agreement related to patent matters. The companies resolved potential patent disputes through negotiation, demonstrating industry practice of managing IP portfolios and avoiding costly litigation.

Strategic tierCoreTypeOthers
Description

Regulatory partnerships and collaborations with global health authorities for drug approvals, clinical trial oversight, and post-marketing surveillance. Wockhardt maintains active engagement with FDA, EMA, WHO Prequalification, and various emerging market regulatory authorities to ensure compliance and expedite approvals.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian pharma peer with branded generics, biosimilars, and API businesses. Has prior commercial relationship with Wockhardt via IP licensing and overlaps in anti-infectives and biosimilars.

TypeDirect peer
Description

Japanese pharmaceutical company with Fetcroja (cefiderocol), a siderophore cephalosporin approved for complicated gram-negative infections. Closely comparable to Wockhardt as a focused anti-infectives innovator targeting carbapenem-resistant pathogens in hospitals.

TypeDirect peer
Description

Indian generic and specialty pharmaceutical company with significant antibiotics exposure and US commercial footprint. Comparable in manufacturing scale and regulatory complexity.

TypeEmerging player
Description

Specialty anti-infectives company with Nuzyra (omadacycline) approved for CABP and acute bacterial skin infections. Comparable as a smaller commercial-stage antibiotic innovator focused on resistance.

TypeDirect peer
Description

Indian pharmaceutical company with strong anti-infectives franchise and US specialty/generics presence. Comparable in therapeutic focus and emerging-market commercialization capabilities.

TypeDirect peer
Description

Indian pharmaceutical peer with overlapping anti-infectives portfolio, strong emerging markets distribution, and growing respiratory and biosimilar franchises. Most directly comparable Indian-listed peer by therapeutic mix and geographic footprint.

TypeBroad incumbent
Description

Markets Recarbrio (imipenem/cilastatin/relebactam) for gram-negative infections and operates a broad hospital anti-infectives portfolio. Direct US hospital competitor to ZAYNICH with established formulary access and IDN relationships.

TypeEmerging player
Description

US-focused anti-infectives company with approved antibiotics targeting resistant pathogens including Baxdela and Orbactiv. Comparable as a specialized, hospital-focused antibiotic company competing for similar formulary slots.

TypeBroad incumbent
Description

Sells Zavicefta (ceftazidime/avibactam) and operates a global hospital anti-infectives franchise. Competes with Wockhardt in the same hospital accounts and IDN formulary committees.

TypeRegional player
Description

Indian biosimilars and pharmaceuticals company with overlap in insulin and biologic franchises comparable to Wockhardt's Glaritus/Wosulin/Wepox portfolio. Most relevant peer for the biosimilars business.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wockhardt

Pharmaceuticalswockhardt.com

Wockhardt firmographics

Firmographics
Name
Wockhardt
Legal name
Wockhardt Limited
Website
https://wockhardt.com
Company type
Public
Founded year
1967
Operating status
Operating
Headcount range
5,001–10,000 employees
Ownership category
akta.pro rank

Wockhardt industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)

Keywords

  • Novel antibiotic development
  • Pharmaceutical manufacturing
  • Biosimilar insulin products
  • Active pharmaceutical ingredients
  • Branded generic medicines

Where Wockhardt is headquartered

Location

Headquarters

HQ city
Mumbai
HQ country
India
HQ region
Asia

Offices5 records

Markets served

Wockhardt business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Branded Generics - India & Emerging Markets: Wockhardt generates significant revenue from its portfolio of branded generic pharmaceuticals sold across India and emerging markets. The company has a strong presence in anti-infectives, with established brands in the Indian pharmaceutical market. Revenue is generated through a network of distributors and field sales representatives targeting hospitals and retail pharmacies.
  2. Biosimilars: Wockhardt has developed and commercializes biosimilar products, including a recent launch of a biosimilar pegfilgrastim (Pegficel) in India. These biologic products provide an alternative to expensive originator biologics and generate revenue through hospital and retail pharmacy channels.
  3. Novel Antibiotics - Zaynich (US & Global Markets): Following FDA approval, Wockhardt is commercializing Zaynich directly in the US market through its own sales force targeting hospital systems. This represents a shift from traditional generic pricing to branded pharmaceutical pricing with premium positioning justified by clinical differentiation and addressing unmet medical needs in antimicrobial resistance.
  4. Contract Manufacturing: Wockhardt operates contract manufacturing services leveraging its USFDA and EMA-approved manufacturing facilities. The company manufactures active pharmaceutical ingredients (APIs) and finished dosage forms for global pharmaceutical companies, providing a steady revenue stream with typically lower margins than branded products.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractZaynich pricing in US market at premium positioning
Unit PricingMulti-year contractZaynich pricing in India at significantly reduced rates

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Wockhardt product offering

Product offering

Core offering

Wockhardt discovers, develops, manufactures, and commercializes pharmaceutical products with a primary focus on novel antibiotics targeting drug-resistant bacterial infections. Its commercial portfolio includes ZAYNICH, EMROK, EMROK O, and Miqnaf/Nafithromycin, alongside biosimilars (Glaritus, Wosulin, Wepox), active pharmaceutical ingredients (APIs), contract manufacturing services for global pharma companies, and a broad branded generics portfolio sold across India and emerging markets.

Product overview

Wockhardt is a research-based pharmaceutical company operating as an integrated enterprise with 'Concept to Commercialisation' capabilities. The company's product portfolio centers on novel antibiotic discovery, with key products including ZAYNICH (a novel IV antibiotic for resistant Gram-negative infections), EMROK/EMROK O (novel antibiotics for MRSA and Gram-positive infections), Nafithromycin/Miqnaf (respiratory antibiotics), and WCK 4282/WCK 6777 (pipeline antibiotics targeting multi-drug resistant pathogens). The biologics division offers insulin products including Glaritus (biosimilar insulin glargine), Wosulin (human insulin), and Wepox (erythropoietin). Additional business segments include Active Pharmaceutical Ingredients (one of the largest Dextromethorphan HBr manufacturers globally), contract manufacturing services across 15 facilities, and quality generic pharmaceuticals. The company holds 45 patents in biosimilar development and 16 patents for insulin pen technology.

Differentiator

Problem solved

Functional benefit

Brands

  • ZAYNICH (Zidebactam/Cefepime): Novel antibiotic for complicated urinary tract infections, first NCE fully developed by an Indian pharma company to receive US FDA approval
  • EMROK / EMROK O
  • Miqnaf (Nafithromycin)
  • Glaritus
  • Wosulin
  • Wepox

Products and services

  • ZAYNICH (Zidebactam/Cefepime - WCK 5222) Novel intravenous antibiotic combining Zidebactam with Cefepime, targeting multi-drug resistant Gram-negative bacteria causing complicated urinary tract infections including pyelonephritis. Designed for hospitalized patients with carbapenem-resistant infections; offered to US hospitals at $10,000-$12,000 per treatment course and at 75-80% lower pricing in India.
  • EMROK (Levonadifloxacin - WCK 771) First-in-class antibiotic derived from the benzoquinolizine structural sub-class, approved for acute bacterial skin and skin structure infections including diabetic-foot infections and concurrent bacteraemia caused by Gram-positive pathogens including MRSA. Designated QIDP by US FDA.
  • EMROK O (Alalevonadifloxacin - WCK 2349) Oral antibiotic prodrug of levonadifloxacin with approximately 90% oral bioavailability, designed for MDR Gram-positive MRSA infections. No dose adjustments required for renal or hepatic impairment. Designated QIDP by US FDA.
  • Miqnaf (Nafithromycin - WCK 4873) Novel oral respiratory antibiotic with an ultra-short-course dosing regimen (800mg once-daily for 3 days) for treatment of community-acquired bacterial pneumonia. Highly potent against respiratory pathogens regardless of azithromycin, penicillin, or quinolone resistance. Designated QIDP by US FDA.
  • WCK 4282 (Cefepime/Tazobactam) Globally patented, pharmacodynamically optimised high-dose combination of cefepime and tazobactam for ESBL-producing Gram-negative pathogens, designed as a superior replacement for piperacillin/tazobactam in Phase 3 development. Designated QIDP by US FDA.
  • WCK 6777 (Ertapenem/Zidebactam) Once-daily IV antibiotic combination designed as outpatient parenteral antimicrobial therapy (OPAT) for multi-drug resistant Gram-negative infections. Phase 1 trials completed in the US with NIAID/NIH; granted Fast Track designation and QIDP status by US FDA.
  • Glaritus (Insulin Glargine) Long-acting biosimilar insulin glargine (100IU/ML) for diabetes treatment, available in vials and cartridges with an in-house developed insulin pen. Backed by 16 globally valid patents for the insulin pen valid until 2035.
  • Wosulin (Recombinant Human Insulin) Recombinant human insulin (r-DNA origin) for diabetes management, sold primarily in India and emerging markets.
  • Wepox (Recombinant Erythropoietin) Recombinant human erythropoietin (r-DNA origin) available in 10 strengths for anemia treatment, marketed globally.
  • Active Pharmaceutical Ingredients (APIs) Active pharmaceutical ingredients manufactured for global supply, including position as one of the largest manufacturers of Dextromethorphan HBr API globally. Over 140 ANDAs in the US and over 60 EU CTD format dossiers developed using complex technologies.
  • Contract Manufacturing Services Contract manufacturing of APIs and finished dosage forms for global pharmaceutical companies, leveraging 12-15 facilities approved by UK MHRA, ANVISA, Gulf GCC, WHO GMP, and US FDA. Full turnkey services from development to high-volume commercial manufacture, including sterile manufacturing capabilities (notably for vaccines and injectables).
  • Quality Generics Portfolio Extensive portfolio of generic pharmaceuticals spanning antibiotics, cardiac medications, analgesics, corticosteroids, proton pump inhibitors, and other therapeutic categories, marketed globally including India, UK, Ireland, Russia-CIS, and emerging markets.

Quantifiable outcome

  • First Indian company to receive FDA approval for a novel antibiotic addressing drug-resistant gram-negative infections
  • +2 more outcomes

Companies that use Wockhardt

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Wockhardt technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Wockhardt partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered major, core and minor.

  • Serum Institute of IndiamajorStrategic or Co-development Partner · 15 January 2024Strategic manufacturing partnership for vaccine production in the UK, leveraging Wockhardt's fill-finish capabilities and regulatory-approved manufacturing facilities. This partnership enabled rapid deployment of COVID-19 vaccines in the UK market during the pandemic, demonstrating Wockhardt's ability to serve as a trusted manufacturing partner for global health initiatives.
  • AstraZeneca/Oxford UniversitymajorStrategic or Co-development PartnerWockhardt manufactured the Oxford-AstraZeneca COVID-19 vaccine (Covishield) for the Indian market, utilizing its fill-finish capabilities and regulatory infrastructure. This partnership involved technology transfer and manufacturing scale-up to produce hundreds of millions of vaccine doses.
  • Government of India - BIRACcoreStrategic or Co-development PartnerResearch partnership with BIRAC (Biotechnology Industry Research Assistance Council) for development of novel antibiotics addressing antimicrobial resistance. BIRAC has supported Wockhardt's R&D programs through funding and regulatory facilitation, reflecting the government's commitment to building indigenous pharmaceutical innovation capabilities.
  • Dr. Reddy's LaboratoriesminorOthersIntellectual property settlement and licensing agreement related to patent matters. The companies resolved potential patent disputes through negotiation, demonstrating industry practice of managing IP portfolios and avoiding costly litigation.
  • Global Regulatory Authorities (FDA, EMA, WHO)coreOthersRegulatory partnerships and collaborations with global health authorities for drug approvals, clinical trial oversight, and post-marketing surveillance. Wockhardt maintains active engagement with FDA, EMA, WHO Prequalification, and various emerging market regulatory authorities to ensure compliance and expedite approvals.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Wockhardt competitors and assessment

Company assessment

Direct peers

  • Dr. Reddy's Laboratories: Indian pharma peer with branded generics, biosimilars, and API businesses. Has prior commercial relationship with Wockhardt via IP licensing and overlaps in anti-infectives and biosimilars.
  • Shionogi & Co., Ltd. Japanese pharmaceutical company with Fetcroja (cefiderocol), a siderophore cephalosporin approved for complicated gram-negative infections. Closely comparable to Wockhardt as a focused anti-infectives innovator targeting carbapenem-resistant pathogens in hospitals.
  • Aurobindo Pharma: Indian generic and specialty pharmaceutical company with significant antibiotics exposure and US commercial footprint. Comparable in manufacturing scale and regulatory complexity.
  • Lupin Limited: Indian pharmaceutical company with strong anti-infectives franchise and US specialty/generics presence. Comparable in therapeutic focus and emerging-market commercialization capabilities.
  • Cipla Limited: Indian pharmaceutical peer with overlapping anti-infectives portfolio, strong emerging markets distribution, and growing respiratory and biosimilar franchises. Most directly comparable Indian-listed peer by therapeutic mix and geographic footprint.

Emerging players

  • Paratek Pharmaceuticals: Specialty anti-infectives company with Nuzyra (omadacycline) approved for CABP and acute bacterial skin infections. Comparable as a smaller commercial-stage antibiotic innovator focused on resistance.
  • Melinta Therapeutics: US-focused anti-infectives company with approved antibiotics targeting resistant pathogens including Baxdela and Orbactiv. Comparable as a specialized, hospital-focused antibiotic company competing for similar formulary slots.

Broad incumbents

  • Merck & Co. Markets Recarbrio (imipenem/cilastatin/relebactam) for gram-negative infections and operates a broad hospital anti-infectives portfolio. Direct US hospital competitor to ZAYNICH with established formulary access and IDN relationships.
  • Pfizer: Sells Zavicefta (ceftazidime/avibactam) and operates a global hospital anti-infectives franchise. Competes with Wockhardt in the same hospital accounts and IDN formulary committees.

Regional players

  • Biocon Limited: Indian biosimilars and pharmaceuticals company with overlap in insulin and biologic franchises comparable to Wockhardt's Glaritus/Wosulin/Wepox portfolio. Most relevant peer for the biosimilars business.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Wockhardt social profiles

Digital presence

Wockhardt compliance and trust

Trust signal

Compliance6 records

Wockhardt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wockhardt leadership team

Management profile

Number of profiles

Profiles4 records

Wockhardt subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Wockhardt funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wockhardt M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wockhardt

What does Wockhardt do?

Wockhardt discovers, develops, manufactures, and commercializes pharmaceutical products with a primary focus on novel antibiotics targeting drug-resistant bacterial infections. Its commercial portfolio includes ZAYNICH, EMROK, EMROK O, and Miqnaf/Nafithromycin, alongside biosimilars (Glaritus, Wosulin, Wepox), active pharmaceutical ingredients (APIs), contract manufacturing services for global pharma companies, and a broad branded generics portfolio sold across India and emerging markets.

Is Wockhardt a public or private company?

Wockhardt is a public company. It is classified as public and is currently operating.

When was Wockhardt founded?

Wockhardt was founded in 1967. It employs 5,001 to 10,000 people.

Where is Wockhardt based?

Wockhardt is headquartered in Mumbai, India, in the Asia region.

How does Wockhardt make money?

Four revenue lines are on record. Branded Generics - India & Emerging Markets are the primary driver. The others are biosimilars, novel Antibiotics - Zaynich (US & Global Markets) and contract Manufacturing.

Who are Wockhardt's main competitors?

Direct peers on record are Dr. Reddy's Laboratories, Shionogi & Co., Ltd., Aurobindo Pharma, Lupin Limited and Cipla Limited. Emerging players are Paratek Pharmaceuticals and Melinta Therapeutics. Broad incumbents are Merck & Co. and Pfizer. Biocon Limited is listed as a regional player.

Does Wockhardt have an API?

No public API is recorded for Wockhardt.

What industry is Wockhardt in?

Wockhardt's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business News TodayWockhardt turns to scientific publications to accelerate Zaynich adoption in US- Moneycontrol.comWockhardt is preparing to launch its antibiotic Zaynich in the US and India, supported by scientific publications. The drug, approved for complicated urinary tract infections, is the first Indian-developed drug to gain USFDA approval. The company will market it directly in the US, with a global Phase III trial accepted for publication in JAMA.TradingViewWockhardt turns to scientific publications to accelerate Zaynich adoption in USWockhardt is preparing to launch its antibiotic Zaynich in the US and India, supported by scientific publications. The drug, approved for complicated urinary tract infections, is the first Indian-developed drug to gain USFDA approval. The company also filed a New Drug Application for Foviscu and is expanding manufacturing for its diabetes biosimilars.The Times of IndiaWockhardt seeks 14-year data shield for India-made drugsWockhardt chairman Habil Khorakiwala urged India to grant 12-14 years of regulatory data protection for domestically developed drugs, citing delays in approval and lack of incentives. He noted innovative drugs launch in India 3.95 years later than globally, and called for better coordination between patent and regulatory agencies.The Times of IndiaWockhardt seeks 14-year data shield for India-made drugsWockhardt, a Mumbai-based drug maker, advocated for 12-14 years of data protection for Indian innovations, citing delays in regulatory approval. The company secured approvals for Zaynich, an antibiotic for urinary tract infections, and noted that innovative drugs launch in India 3.95 years later than globally.CNBCTV18Here are five pharma and healthcare stocks that will be reacting to their Q2 results today - CNBC TV18Five pharma and healthcare stocks—Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs—reported their September quarter results on November 3. Granules India saw revenue growth but margin softening, while Akums Drugs reported net profit more than doubling to ₹112.8 crore. The results were reported after market hours on Monday.TradingViewNews by CNBC TV18 on TradingView, 2026-11-03Five pharma and healthcare stocks reported Q2 results on November 3, with Granules India, Wockhardt, SPARC, Krsnaa Diagnostics, and Akums Drugs all posting revenue and profit figures. Akums Drugs saw net profit more than double to ₹112.8 crore, while SPARC's losses narrowed to ₹24.96 crore. The results were reported after market hours on Monday.ScanXStocks to Watch Today, November 3, 2026: Marico, Petronet LNG, KRBL, Wockhardt and VRL LogisticsVRL Logistics surged 7.3% on a 106% profit jump and buyback, while KRBL rose 5.2% on a 51% profit increase. Petronet LNG gained 4% after filing a GST writ petition, and ITC slipped on margin contraction. Marico's board appointed Rohit Jawa as additional independent director.ScanXStocks to Watch Today, November 3, 2026: Marico, Petronet LNG, KRBL, Wockhardt and VRL LogisticsOn November 3, 2026, mid-cap stocks like VRL Logistics and KRBL rallied on profit beats, while large-cap ITC remained flat on margin contraction. VRL Logistics gained 7.3% on a 106% YoY profit jump, KRBL surged 5.2% on a 51% profit rise, and Petronet LNG rose 4% on a dividend declaration.CNBCTV18Wockhardt Q2 results: Revenue jumps 24%, but profit barely grows as margins shrink - CNBC TV18Wockhardt reported Q2 revenue of ₹969 crore, up 23.9% year-on-year, but net profit rose only 1.3% to ₹79 crore as margins contracted. Biotech revenue grew 68% to ₹252 crore, while EBITDA margin fell to 17.9% from 22.8%.The Times of IndiaWockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%Wockhardt expanded marketing access to its antibiotic Miqnaf in India after the DCGI removed a supply condition. The company reported a 24% year-on-year revenue increase to ₹969 crore in Q2 FY27, while consolidated PAT fell to ₹73 crore. It plans to file for an additional indication for Miqnaf in the third or fourth quarter of FY27.